Palatin Technologies (PTN) 0.90 $PTN
Female Sexual Dysfunction Therapeutics Pipeline Review, H2 2014 - 4 Companies & 9 Drug Profiles
M2 - Fri Sep 12, 4:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qffhrg/female_sexual) has announced the addition of the "Female Sexual Dysfunction - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Female Sexual Dysfunction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Female Sexual Dysfunction and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Palatin Technologies, Inc. - M et P Pharma AG - ANI Pharmaceuticals, Inc. - EndoCeutics, Inc. Drug Profiles - testosterone - prasterone - bremelanotide - (bupropion hydrochloride trazodone hydrochloride) - TBS-2 - PL-6983 - S1B-307 - S1B-3006 - Next Generation Melanocortin Receptor IV Agonist For more information visit http://www.researchandmarkets.com/research/qf...ale_sexual
Global Chronic Heart Failure Therapeutics Pipeline Review 2014 - 21 Companies & 31 Drug Profiles
M2 - Thu Sep 11, 4:24AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wx7flm/chronic_heart) has announced the addition of the "Chronic Heart Failure - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Heart Failure, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Heart Failure and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Hospira, Inc. - Amgen Inc. - Sanofi - Novartis AG - Laboratoires Pierre Fabre SA - Les Laboratoires Servier SAS - Pfizer Inc. - Bayer AG - Celladon Corporation - Mesoblast Limited - Palatin Technologies, Inc. - AnGes MG, Inc. - MetrioPharm AG - Cyano Biotech GmbH - NormOxys, Inc. - Cardioxyl Pharmaceuticals, Inc. - PhaseBio Pharmaceuticals, Inc. - miRagen Therapeutics, Inc. - Fibrotech Therapeutics Pty. Ltd. - Otsuka Holdings Co., Ltd. - Zensun (Shanghai) Sci & Tech Co., Ltd. Drug Profiles - Neucardin - rivaroxaban - (sacubitril valsartan) - CEP-41750 - aliskiren fumarate - sildenafil citrate - ivabradine - PL-3994 - omecamtiv mecarbil - Mydicar - CXL-1020 - serelaxin (recombinant) - tolvaptan - finerenone - ivabradine - F-373280 - Stem Cell Therapy for Cardiovascular Diseases - cenderitide - beperminogene perplasmid - OXY-111A - Small Molecule to Inhibit Beta-1 Adrenergic Receptor for Chronic Heart Failure - MGN-9103 - BR-5489 - FT-011 - PB-1046 - Cell Therapy for Chronic Heart Failure - SAR-296968 - RNAi Gene Therapy to Inhibit STIM1 for Cardiovascular Diseases - Peptides Inhibiting ACE for Cardiovascular and Metabolic Disorders - Vestiras For more information visit http://www.researchandmarkets.com/research/wx...onic_heart
Will Lululemon's (LULU) Drab Earnings Trend Repeat in Q2? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 09, 10:30AM CDT
Lululemon Athletica Inc. (LULU), a leading yoga-inspired athletic apparel and accessories retailer, is slated to report its second-quarter fiscal 2014 results on Sep 11, 2014.
Palatin Technologies posts lower net loss of USD4.3m for Q4 2014
M2 - Tue Sep 09, 6:52AM CDT
Biopharmaceutical company Palatin Technologies (NYSE MKT
TN) on Tuesday reported a net loss of USD4.3m (USD0.04 per basic and diluted share) for its fourth quarter ended 30 June 2014.
Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2014 Results
PR Newswire - Tue Sep 09, 6:30AM CDT
Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced results for its fourth quarter and fiscal year ended June 30, 2014.
Palatin Technologies, Inc. To Report Fourth Quarter and Fiscal Year 2014 Results
PR Newswire - Thu Sep 04, 3:58PM CDT
Palatin Technologies, Inc. (NYSE MKT: PTN) will announce its fourth quarter, fiscal year 2014 operating results on Tuesday, September 9, 2014 before the open of the U.S. financial markets.
Palatin Technologies and Richter enter into license agreement for FSD bremelanotide in Europe and other selected countries
M2 - Thu Sep 04, 8:40AM CDT
Biopharmaceutical company Palatin Technologies (NYSE MKT TN) said on Wednesday that it has entered into a collaboration and license agreement to co-develop and commercialise bremelanotide for female sexual dysfunction (FSD) indications in the EU, other European countries and additional selected countries, with European-based specialty pharmaceutical company Gedeon Richter Plc.
Palatin Technologies Licenses Bremelanotide in Europe and Other Selected Countries to Richter
PR Newswire - Wed Sep 03, 1:00AM CDT
Palatin Technologies, Inc. (NYSE MKT: PTN; hereinafter: "Palatin"
and Gedeon Richter Plc. (hereinafter: "Richter" announced that they have entered into a collaboration and license agreement to co-develop and commercialize bremelanotide for female sexual dysfunction (FSD) indications in the European Union, other European countries and additional selected countries. Richter is a European-based specialty pharmaceutical company with a strong focus in female health and annual sales of more than EUR 1.2 billion ($1.6 billion).
Palatin Technologies Announces Notification of Patent Allowance On Melanocortin Receptor-1 Specific Peptides
PR Newswire - Wed Jul 09, 6:30AM CDT
Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application Serial Number 13/910,422 (the '422 application). The application includes composition of matter claims on broad families of melanocortin receptor--1 specific peptides with potential utility for treatment of inflammatory diseases and disorders.
Palatin Technologies to Join Russell Microcap Index
PR Newswire - Fri Jun 27, 6:30AM CDT
Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, announced that it is joining the Russell Microcap® Index when Russell Investments reconstitutes its comprehensive set of U.S. and global equity indexes later today. Palatin was included on a preliminary list of additions posted on www.russell.com/indexes.
Palatin Technologies Inc. (PTN) Jumps: Stock Up 8.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 02, 7:51AM CDT
Palatin Technologies Inc. was a big mover last session, as its shares rose over 8% on the day.
Palatin Technologies' option to license out Bremelanotide in Europe extended until 30 April 2014
M2 - Tue Apr 01, 6:32AM CDT
Biopharmaceutical company Palatin Technologies (NYSE MKT TN) said on Monday that it has received an extension until 30 April 2014 to an existing option agreement with a potential European partner for an exclusive license to the former's bremelanotide for female sexual dysfunction in selected European countries, including the EU.
Palatin Technologies Announces Option Extension for License to Bremelanotide in Europe
PR Newswire - Mon Mar 31, 3:15PM CDT
Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, announced that it has granted an extension until April 30, 2014 to an existing option agreement with a potential commercial partner for an exclusive license to bremelanotide for female sexual dysfunction indications in selected European countries, including the European Union.
Morning Briefing on Stocks hitting New Milestones -- Research on Finisar, Analog Devices, Palatin Technologies and Green Plains Renewable
PR Newswire - Fri Mar 21, 5:04PM CDT
On Thursday, March 20, 2014, the NASDAQ Composite finished at 4,319.29, up 0.27%. The Dow Jones Industrial Average closed the session at 16,331.05, up 0.67% and the S&P 500 ended the day at 1,872.01, higher by 0.60%. The gains were broad based with nine out of 10 sectors ending the session in positive. Investor-Edge looks at some of the equities that hit a new 52-week high during the last session. These include Finisar Corp. (NASDAQ: FNSR), Analog Devices Inc. (NASDAQ: ADI), Palatin Technologies Inc. (AMEX: PTN) and Green Plains Renewable Energy Inc. (NASDAQ: GPRE). Free technical research on FNSR, ADI, PTN and GPRE can be downloaded upon signing up at:
Palatin Technologies (PTN) Worth Watching: Stock Soars 15.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Mar 20, 8:25AM CDT
Palatin was a big mover last session, with shares rising nearly 16% on the day.
Palatin Technologies To Present At The 26Th Annual ROTH Conference
PR Newswire - Thu Mar 06, 6:30AM CST
Palatin Technologies, Inc. (NYSE MKT: PTN) announced that it will be presenting at the 26th Annual ROTH Conference on Tuesday, March 11, 2014, at 3:30 p.m. Pacific Time. The conference will be held at the Ritz Carlton Laguna Niguel in Dana Point, CA.
Palatin Technologies Presents Positive New Data Analyses Demonstrating Efficacy of Bremelanotide in Female Hypoactive Sexual Desire Disorder
PR Newswire - Mon Feb 24, 6:30AM CST
Palatin Technologies, Inc. (NYSE MKT: PTN) presented new analyses from its Phase 2b clinical trial of bremelanotide, which demonstrated dose-dependent improvements in sexual desire and treatment satisfaction in premenopausal women with hypoactive sexual desire disorder (HSDD) and combined HSDD/female sexual arousal disorder (FSAD), both which are forms of female sexual dysfunction (FSD).1,2,3
Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2014 Results; Teleconference and Webcast to be held on February 18, 2014
PR Newswire - Tue Feb 18, 6:30AM CST
Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced results for its second quarter ended December 31, 2013.
Soligenix Announces $300,000 NIAID SBIR Grant Award Supporting Further Evaluation of SGX943 as a Treatment for Melioidosis
PR Newswire - Fri Feb 14, 6:15AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that the National Institute of Allergy and Infectious Diseases (NIAID) has awarded Soligenix a Small Business Innovation Research (SBIR) grant to support further preclinical development of SGX943 as a treatment for melioidosis. The award will provide Soligenix with approximately $300,000 over one year to conduct the studies in collaboration with Tulane University.
Palatin Technologies, Inc. To Report Second Quarter Fiscal Year 2014 Results
PR Newswire - Thu Feb 13, 6:30AM CST
Palatin Technologies, Inc. (NYSE MKT: PTN) will announce its second quarter, fiscal year 2014 operating results on Tuesday, February 18, 2014 before the open of the U.S. financial markets.
Female Sexual Dysfunction Therapeutics Pipeline Review, H2 2014 - 4 Companies & 9 Drug Profiles
M2 - Fri Sep 12, 4:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qffhrg/female_sexual) has announced the addition of the "Female Sexual Dysfunction - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Female Sexual Dysfunction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Female Sexual Dysfunction and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Palatin Technologies, Inc. - M et P Pharma AG - ANI Pharmaceuticals, Inc. - EndoCeutics, Inc. Drug Profiles - testosterone - prasterone - bremelanotide - (bupropion hydrochloride trazodone hydrochloride) - TBS-2 - PL-6983 - S1B-307 - S1B-3006 - Next Generation Melanocortin Receptor IV Agonist For more information visit http://www.researchandmarkets.com/research/qf...ale_sexual
Global Chronic Heart Failure Therapeutics Pipeline Review 2014 - 21 Companies & 31 Drug Profiles
M2 - Thu Sep 11, 4:24AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wx7flm/chronic_heart) has announced the addition of the "Chronic Heart Failure - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Heart Failure, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Heart Failure and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Hospira, Inc. - Amgen Inc. - Sanofi - Novartis AG - Laboratoires Pierre Fabre SA - Les Laboratoires Servier SAS - Pfizer Inc. - Bayer AG - Celladon Corporation - Mesoblast Limited - Palatin Technologies, Inc. - AnGes MG, Inc. - MetrioPharm AG - Cyano Biotech GmbH - NormOxys, Inc. - Cardioxyl Pharmaceuticals, Inc. - PhaseBio Pharmaceuticals, Inc. - miRagen Therapeutics, Inc. - Fibrotech Therapeutics Pty. Ltd. - Otsuka Holdings Co., Ltd. - Zensun (Shanghai) Sci & Tech Co., Ltd. Drug Profiles - Neucardin - rivaroxaban - (sacubitril valsartan) - CEP-41750 - aliskiren fumarate - sildenafil citrate - ivabradine - PL-3994 - omecamtiv mecarbil - Mydicar - CXL-1020 - serelaxin (recombinant) - tolvaptan - finerenone - ivabradine - F-373280 - Stem Cell Therapy for Cardiovascular Diseases - cenderitide - beperminogene perplasmid - OXY-111A - Small Molecule to Inhibit Beta-1 Adrenergic Receptor for Chronic Heart Failure - MGN-9103 - BR-5489 - FT-011 - PB-1046 - Cell Therapy for Chronic Heart Failure - SAR-296968 - RNAi Gene Therapy to Inhibit STIM1 for Cardiovascular Diseases - Peptides Inhibiting ACE for Cardiovascular and Metabolic Disorders - Vestiras For more information visit http://www.researchandmarkets.com/research/wx...onic_heart
Will Lululemon's (LULU) Drab Earnings Trend Repeat in Q2? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 09, 10:30AM CDT
Lululemon Athletica Inc. (LULU), a leading yoga-inspired athletic apparel and accessories retailer, is slated to report its second-quarter fiscal 2014 results on Sep 11, 2014.
Palatin Technologies posts lower net loss of USD4.3m for Q4 2014
M2 - Tue Sep 09, 6:52AM CDT
Biopharmaceutical company Palatin Technologies (NYSE MKT
TN) on Tuesday reported a net loss of USD4.3m (USD0.04 per basic and diluted share) for its fourth quarter ended 30 June 2014. Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2014 Results
PR Newswire - Tue Sep 09, 6:30AM CDT
Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced results for its fourth quarter and fiscal year ended June 30, 2014.
Palatin Technologies, Inc. To Report Fourth Quarter and Fiscal Year 2014 Results
PR Newswire - Thu Sep 04, 3:58PM CDT
Palatin Technologies, Inc. (NYSE MKT: PTN) will announce its fourth quarter, fiscal year 2014 operating results on Tuesday, September 9, 2014 before the open of the U.S. financial markets.
Palatin Technologies and Richter enter into license agreement for FSD bremelanotide in Europe and other selected countries
M2 - Thu Sep 04, 8:40AM CDT
Biopharmaceutical company Palatin Technologies (NYSE MKT
TN) said on Wednesday that it has entered into a collaboration and license agreement to co-develop and commercialise bremelanotide for female sexual dysfunction (FSD) indications in the EU, other European countries and additional selected countries, with European-based specialty pharmaceutical company Gedeon Richter Plc. Palatin Technologies Licenses Bremelanotide in Europe and Other Selected Countries to Richter
PR Newswire - Wed Sep 03, 1:00AM CDT
Palatin Technologies, Inc. (NYSE MKT: PTN; hereinafter: "Palatin"
and Gedeon Richter Plc. (hereinafter: "Richter" announced that they have entered into a collaboration and license agreement to co-develop and commercialize bremelanotide for female sexual dysfunction (FSD) indications in the European Union, other European countries and additional selected countries. Richter is a European-based specialty pharmaceutical company with a strong focus in female health and annual sales of more than EUR 1.2 billion ($1.6 billion). Palatin Technologies Announces Notification of Patent Allowance On Melanocortin Receptor-1 Specific Peptides
PR Newswire - Wed Jul 09, 6:30AM CDT
Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application Serial Number 13/910,422 (the '422 application). The application includes composition of matter claims on broad families of melanocortin receptor--1 specific peptides with potential utility for treatment of inflammatory diseases and disorders.
Palatin Technologies to Join Russell Microcap Index
PR Newswire - Fri Jun 27, 6:30AM CDT
Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, announced that it is joining the Russell Microcap® Index when Russell Investments reconstitutes its comprehensive set of U.S. and global equity indexes later today. Palatin was included on a preliminary list of additions posted on www.russell.com/indexes.
Palatin Technologies Inc. (PTN) Jumps: Stock Up 8.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 02, 7:51AM CDT
Palatin Technologies Inc. was a big mover last session, as its shares rose over 8% on the day.
Palatin Technologies' option to license out Bremelanotide in Europe extended until 30 April 2014
M2 - Tue Apr 01, 6:32AM CDT
Biopharmaceutical company Palatin Technologies (NYSE MKT
TN) said on Monday that it has received an extension until 30 April 2014 to an existing option agreement with a potential European partner for an exclusive license to the former's bremelanotide for female sexual dysfunction in selected European countries, including the EU. Palatin Technologies Announces Option Extension for License to Bremelanotide in Europe
PR Newswire - Mon Mar 31, 3:15PM CDT
Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, announced that it has granted an extension until April 30, 2014 to an existing option agreement with a potential commercial partner for an exclusive license to bremelanotide for female sexual dysfunction indications in selected European countries, including the European Union.
Morning Briefing on Stocks hitting New Milestones -- Research on Finisar, Analog Devices, Palatin Technologies and Green Plains Renewable
PR Newswire - Fri Mar 21, 5:04PM CDT
On Thursday, March 20, 2014, the NASDAQ Composite finished at 4,319.29, up 0.27%. The Dow Jones Industrial Average closed the session at 16,331.05, up 0.67% and the S&P 500 ended the day at 1,872.01, higher by 0.60%. The gains were broad based with nine out of 10 sectors ending the session in positive. Investor-Edge looks at some of the equities that hit a new 52-week high during the last session. These include Finisar Corp. (NASDAQ: FNSR), Analog Devices Inc. (NASDAQ: ADI), Palatin Technologies Inc. (AMEX: PTN) and Green Plains Renewable Energy Inc. (NASDAQ: GPRE). Free technical research on FNSR, ADI, PTN and GPRE can be downloaded upon signing up at:
Palatin Technologies (PTN) Worth Watching: Stock Soars 15.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Mar 20, 8:25AM CDT
Palatin was a big mover last session, with shares rising nearly 16% on the day.
Palatin Technologies To Present At The 26Th Annual ROTH Conference
PR Newswire - Thu Mar 06, 6:30AM CST
Palatin Technologies, Inc. (NYSE MKT: PTN) announced that it will be presenting at the 26th Annual ROTH Conference on Tuesday, March 11, 2014, at 3:30 p.m. Pacific Time. The conference will be held at the Ritz Carlton Laguna Niguel in Dana Point, CA.
Palatin Technologies Presents Positive New Data Analyses Demonstrating Efficacy of Bremelanotide in Female Hypoactive Sexual Desire Disorder
PR Newswire - Mon Feb 24, 6:30AM CST
Palatin Technologies, Inc. (NYSE MKT: PTN) presented new analyses from its Phase 2b clinical trial of bremelanotide, which demonstrated dose-dependent improvements in sexual desire and treatment satisfaction in premenopausal women with hypoactive sexual desire disorder (HSDD) and combined HSDD/female sexual arousal disorder (FSAD), both which are forms of female sexual dysfunction (FSD).1,2,3
Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2014 Results; Teleconference and Webcast to be held on February 18, 2014
PR Newswire - Tue Feb 18, 6:30AM CST
Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced results for its second quarter ended December 31, 2013.
Soligenix Announces $300,000 NIAID SBIR Grant Award Supporting Further Evaluation of SGX943 as a Treatment for Melioidosis
PR Newswire - Fri Feb 14, 6:15AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that the National Institute of Allergy and Infectious Diseases (NIAID) has awarded Soligenix a Small Business Innovation Research (SBIR) grant to support further preclinical development of SGX943 as a treatment for melioidosis. The award will provide Soligenix with approximately $300,000 over one year to conduct the studies in collaboration with Tulane University.
Palatin Technologies, Inc. To Report Second Quarter Fiscal Year 2014 Results
PR Newswire - Thu Feb 13, 6:30AM CST
Palatin Technologies, Inc. (NYSE MKT: PTN) will announce its second quarter, fiscal year 2014 operating results on Tuesday, February 18, 2014 before the open of the U.S. financial markets.
